BrightInsight, the Silicon Valley-headquartered digital health company focused on connected care for chronic conditions, has closed a $13 million growth investment to further scale its AI-powered medication adherence platform. The round, finalised in mid-January 2026, was led by existing investors with strong participation from strategic partners in the pharmaceutical and healthcare sectors, reflecting continued confidence in BrightInsight’s ability to deliver measurable improvements in patient outcomes and therapeutic value.

Medication non-adherence remains one of the most expensive and preventable problems in modern healthcare, costing global health systems hundreds of billions of dollars annually and contributing to avoidable hospitalisations, disease progression, and reduced quality of life. BrightInsight’s platform tackles this challenge head-on by combining smart connected devices (such as sensor-enabled packaging and inhalers), real-time behavioural analytics, personalised nudges, and AI-driven risk stratification to predict and prevent missed doses before they occur.

The system integrates seamlessly with pharmaceutical sponsor programmes, providing sponsors with anonymised real-world adherence data while delivering patients tailored support through mobile apps, voice reminders, educational content, and escalation to care teams when needed. Clinical studies and real-world deployments have consistently shown adherence improvements of 20–40% across multiple chronic conditions, including diabetes, multiple sclerosis, cardiovascular disease, and immunology therapies.

BrightInsight CEO and Co-founder Rahul Chopra commented: “Non-adherence is not just a patient problem 1it’s a systemic one. Our platform uses AI to understand behaviour at an individual level and intervene at the right moment with the right message. This funding allows us to scale that capability across more therapies and geographies, ultimately helping millions stay on treatment longer and achieve better health outcomes.”

The new capital will be deployed to:

• Expand into additional high-need therapeutic areas, including respiratory, oncology supportive care, and rare diseases
• Enhance AI models for predictive adherence risk scoring and personalised intervention design
• Strengthen partnerships with global pharmaceutical companies seeking real-world evidence and differentiated patient support programmes
• Accelerate international growth, particularly in Europe and Asia-Pacific markets

BrightInsight’s approach stands out in the crowded digital therapeutics and adherence space by maintaining a strong focus on sponsor-funded, clinically validated solutions rather than direct-to-consumer models. The company’s platform is already used by several top global pharmaceutical brands and has generated significant real-world evidence demonstrating both clinical and economic value.

As healthcare systems worldwide intensify efforts to improve chronic disease management and shift toward value-based care, tools that demonstrably increase adherence are gaining strategic importance. With this latest funding, BrightInsight is well-positioned to capture a larger share of this growing opportunity while continuing to deliver measurable impact for patients, providers, and payers alike.